Companies Dominating the Multiple Myeloma Landscape
- Bristol-Myers Squibb Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Amgen Inc.
- Johnson & Johnson
- Novartis AG
- Sanofi
- Janssen Pharmaceuticals Inc.
- Genentech, Inc.
- AbbVie Inc.
- Karyopharm
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Multiple Myeloma Therapy Market in 2025 is evaluated at USD 22.68 billion.
The global market size was worth around USD 21.74 billion in 2024 and is set to register a CAGR of more than 5.4%, exceeding USD 43.07 billion revenue by 2037.
Asia Pacific is projected to obtain USD 10.77 billion by 2037, attributed to increased government funding in cancer R&D.
The major players in the market include Sanofi, Celgene, Johnson & Johnson, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Novartis AG, Millennium Pharmaceuticals and Innate Pharma SA.
